A

AdAlta
1AD

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
A$2.23M
EV
A$2.23M
Shares Outstanding
1.12B
Beta
-0.05

Wall Street View

Analyst Rating
NOT_AVAILABLE
Analyst Target Price
-
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About AdAlta Limited

gainify

A

AdAlta Limited

1AD

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including id...

Sector

Healthcare

Industry

Biotechnology

CEO

Oldham, Timothy

Employees

9

IPO Date

2016-08-22

Headquarters

La Trobe Institute of Molecular Science, Room 204, LIMS2 Science Drive, La Trobe University, Bundoora, Victoria, 3086, Australia

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.